Sanofi Secures German Regulatory Clearance for Dynavax Acquisition
SNY is trading near its 52-week low of $44.617 (4.4% above the low) on elevated volume (2.3× avg).
Summary
Sanofi announced that it has received German foreign direct investment clearance, a key condition for its tender offer to acquire Dynavax Technologies Corporation.
Key Events · M&A and Partnerships · SNY
-
German FDI Clearance Obtained
The Federal Ministry for Economic Affairs and Energy (BMWK) cleared the acquisition of Dynavax GmbH, a condition for the overall tender offer.
-
Acquisition Progresses
This clearance, effective January 29, 2026, marks another significant step towards completing Sanofi's tender offer for Dynavax Technologies, following the HSR waiting period expiration.
Analysis · SNY · Life Sciences
This amendment signals significant progress towards the completion of Sanofi's acquisition of Dynavax Technologies. The clearance from the German Federal Ministry for Economic Affairs and Energy removes a critical regulatory condition, de-risking the transaction and moving it closer to its expected close. This follows the expiration of the HSR waiting period announced on January 28, 2026, indicating a steady progression through regulatory approvals since the initial tender offer on January 12, 2026.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNY was trading at $46.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $111.8B. The 52-week trading range was $44.62 to $60.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.